Usual Adult Dose for Parkinson's Disease

84 mg via oral inhalation as needed when OFF period starts to return; may dose up to 5 times a day
Maximum dose per OFF period: 84 mg
Maximum daily dose: 420 mg

Comments:

• Therapy should be taken when symptoms of an OFF period start to return.
• This drug has shown efficacy only in combination with levodopa/carbidopa therapy.
• Oral inhalation capsules should only be used with the Inbrija(R) inhaler; capsules should not be swallowed whole as the intended effect will not be obtained.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Concomitant, or within 2 weeks of taking a nonselective monoamine oxidase (MAO) inhibitor such as phenelzine or tranylcypromine

Dialysis

Data not available

Other Comments

Administration advice:

• Capsules are for oral inhalation with the Inbrija(R) inhaler
• Capsules must not be swallowed
• Each dose requires 2 capsules for a total of 84 mg; dosing is for the intermittent treatment of OFF episodes, taken as needed, up to 5 doses in a 24-hour period
• Patients should be instructed in the proper administration prior to use

• Store capsules in a dry place; capsules should be kept in blister package until just before use
• Do not store capsules in the inhaler

• In clinical trials, patients used approximately 2 doses per day.

• Patients should be instructed to read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
• Patients should understand that this drug is taken as needed when symptoms of an OFF period first occur and does not replace their daily carbidopa-levodopa medication.
• Patients should understand that inhalation may lead to coughing.
• Patients should understand that this medication may cause a dark coloration of saliva, urine, or sweat; this coloration is clinically insignificant.
• Patients should be advised that falling asleep during activities of daily living, including driving, have been reported; sedating effects should be reported to their healthcare provider and they should discuss use of alcohol and/or other sedating medications with their physician.
• Patients should be advised that this drug may cause syncope, new or worsening dyskinesias, hallucinations, depression, and impulse control and/or compulsive behaviors; they should speak with their healthcare provider if these develop.

Frequently asked questions

• How long does it take carbidopa levodopa to work?
• What foods should be avoided when taking levodopa?
• How often should carbidopa/levodopa be taken?
• Can carbidopa/levodopa cause high blood pressure?
• What is the difference between carbidopa, levodopa, and Rytary?
• How does it help Parkinson's disease?
• How much does Inbrija cost?
• When is the best time to take Ongentys?